Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NASDAQ:DRUG NASDAQ:DSGN NASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.19+2.6%$2.48$1.28▼$7.85$350.54M1.362.49 million shs1.52 million shsDRUGBright Minds Biosciences$53.26-4.9%$43.98$0.94▼$79.02$375.16M-6.1792,677 shs99,754 shsDSGNDesign Therapeutics$6.11+1.7%$5.48$2.60▼$7.77$347.95M1.68195,695 shs81,597 shsHOWLWerewolf Therapeutics$2.05+6.8%$1.45$0.60▼$4.18$93.74M0.76913,378 shs1.03 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%-5.34%+48.37%+7.95%-50.31%DRUGBright Minds Biosciences0.00%+1.02%+21.18%+88.20%+4,667.70%DSGNDesign Therapeutics0.00%-7.00%0.00%+62.07%+22.94%HOWLWerewolf Therapeutics0.00%-0.97%+51.85%+89.64%+1.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$3.19+2.6%$2.48$1.28▼$7.85$350.54M1.362.49 million shs1.52 million shsDRUGBright Minds Biosciences$53.26-4.9%$43.98$0.94▼$79.02$375.16M-6.1792,677 shs99,754 shsDSGNDesign Therapeutics$6.11+1.7%$5.48$2.60▼$7.77$347.95M1.68195,695 shs81,597 shsHOWLWerewolf Therapeutics$2.05+6.8%$1.45$0.60▼$4.18$93.74M0.76913,378 shs1.03 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon0.00%-5.34%+48.37%+7.95%-50.31%DRUGBright Minds Biosciences0.00%+1.02%+21.18%+88.20%+4,667.70%DSGNDesign Therapeutics0.00%-7.00%0.00%+62.07%+22.94%HOWLWerewolf Therapeutics0.00%-0.97%+51.85%+89.64%+1.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.40Hold$12.50291.85% UpsideDRUGBright Minds Biosciences 3.11Buy$81.0052.08% UpsideDSGNDesign Therapeutics 1.00SellN/AN/AHOWLWerewolf Therapeutics 2.67Moderate Buy$8.00290.24% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, DSGN, DRUG, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025ANNXAnnexonWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DSGNDesign TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025HOWLWerewolf TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/15/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.009/8/2025DRUGBright Minds BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/25/2025HOWLWerewolf TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/25/2025HOWLWerewolf TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.008/21/2025HOWLWerewolf TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.008/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.008/18/2025ANNXAnnexonZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/15/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$2.75 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AHOWLWerewolf Therapeutics$1.88M49.87N/AN/A$1.65 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$138.20M-$1.29N/AN/AN/AN/A-70.04%-57.67%11/13/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/ADSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)HOWLWerewolf Therapeutics-$70.51M-$1.64N/AN/AN/AN/A-111.87%-62.68%11/6/2025 (Estimated)Latest HOWL, DSGN, DRUG, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ANNXAnnexon-$0.36-$0.34+$0.02-$0.34N/AN/A8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/14/2025Q2 2025HOWLWerewolf Therapeutics-$0.50-$0.40+$0.10-$0.40$1.50 millionN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A5.675.67DRUGBright Minds BiosciencesN/A86.6486.64DSGNDesign TherapeuticsN/A25.1325.13HOWLWerewolf Therapeutics0.605.305.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/ADRUGBright Minds Biosciences40.52%DSGNDesign Therapeutics56.64%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipANNXAnnexon11.87%DRUGBright Minds Biosciences42.66%DSGNDesign Therapeutics23.50%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.89 million96.84 millionOptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableHOWLWerewolf Therapeutics4045.73 million34.94 millionOptionableHOWL, DSGN, DRUG, and ANNX HeadlinesRecent News About These CompaniesWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual MeetingOctober 3 at 9:23 AM | markets.businessinsider.comWerewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual MeetingOctober 3 at 9:00 AM | globenewswire.comAnalysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Price Target at $8.00September 25, 2025 | americanbankingnews.comWerewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Average Recommendation of "Buy" by BrokeragesSeptember 20, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for HOWL Q3 Earnings?September 9, 2025 | marketbeat.comWerewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?September 8, 2025 | zacks.comBrokers Offer Predictions for HOWL Q1 EarningsSeptember 7, 2025 | marketbeat.comWerewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global ...September 2, 2025 | bakersfield.comBWerewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comWerewolf Therapeutics price target lowered to $3 from $4 at Citizens JMPAugust 22, 2025 | msn.comWerewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA DisruptionsAugust 16, 2025 | msn.comWerewolf Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | tipranks.comWerewolf Therapeutics sees cash runway into 4Q26August 14, 2025 | msn.comWerewolf Therapeutics Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comWerewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comReAlta Life Sciences Appoints Ellen Lubman as Chief Business OfficerJuly 29, 2025 | finance.yahoo.comHowling Hits: The Ultimate List of Must-Watch Werewolf MoviesJuly 17, 2025 | msn.comWerewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research SummitJuly 9, 2025 | globenewswire.comWerewolf Therapeutics, Inc. (HOWL) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comWerewolf Therapeutics to Participate in the BIO International ConventionJune 12, 2025 | globenewswire.comWerewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should KnowMay 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025Eli Lilly’s Oral GLP-1 Breakthrough Could Change EverythingBy Chris Markoch | September 18, 2025HOWL, DSGN, DRUG, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$3.19 +0.08 (+2.57%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.19 0.00 (0.00%) As of 10/3/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Bright Minds Biosciences NASDAQ:DRUG$53.26 -2.74 (-4.89%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$53.74 +0.48 (+0.90%) As of 10/3/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Design Therapeutics NASDAQ:DSGN$6.11 +0.10 (+1.66%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.11 0.00 (0.00%) As of 10/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Werewolf Therapeutics NASDAQ:HOWL$2.05 +0.13 (+6.77%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.04 -0.01 (-0.73%) As of 10/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
